Key points are not available for this paper at this time.
-targeted therapeutics reduce TDP-43 pathology in vivo, and demonstrate that alterations in plasma NFL provide insight into the therapeutic efficacy of disease-modifying treatments.
Cook et al. (Wed,) studied this question.